Home/ Stocks/ KALA

KALA BIO, Inc. Common Stock

KALA XNAS

$0.75 +0.04 (+5.85%) ▲ 15-min delayed

Open

$0.75

High

$0.78

Low

$0.72

Volume

43.1K

Market Cap

$14.25M

About KALA BIO, Inc. Common Stock

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 6 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-1,621,000	$-0.14
FY 2025	$0	$-26,980,000	$-3.31
Q3 2025	$0	$-7,564,000	$-1.07
Q2 2025	$0	$-11,155,000	$-1.71

Related Market News

No specific coverage for KALA yet. Check out our latest market news or earnings calendar.

Get KALA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on KALA BIO, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.